FDA Advisers Vote 12-To-2 In Favor Of Benefits Of Geron's Blood Disorder Drug Outweighing Its Risks Based On Late-Stage Trial Data
Portfolio Pulse from Benzinga Newsdesk
FDA advisers have voted 12-to-2 in favor of the benefits of Geron's blood disorder drug outweighing its risks, based on late-stage trial data, according to Reuters.
March 14, 2024 | 7:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
FDA advisers have strongly supported Geron's blood disorder drug, indicating a positive outlook for its approval based on late-stage trial data.
The strong advisory vote in favor of Geron's drug suggests a high likelihood of FDA approval, which can significantly boost the company's prospects and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100